Anti-interleukin 21 monoclonal antibody - Novo Nordisk

Drug Profile

Anti-interleukin 21 monoclonal antibody - Novo Nordisk

Alternative Names: Anti-IL21; NN-8828; NN-9828; NNC-0114-0000-0005; NNC0114-0006; NNC114-0005

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Interleukin 21 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 01 Nov 2015 Phase-II clinical trials in Type-1 diabetes mellitus (Combination therapy, Newly diagnosed) in Denmark, United Kingdom, Sweden, Ukraine, Spain, Serbia, Russia, Portugal, Italy, Israel, Norway, Ireland, Finland, Austria, Canada, USA (IV)
  • 23 May 2015 Novo Nordisk plans a phase II trial for Type-I diabetes mellitus (Newly diagnosed, Combination therapy) in USA, Austria, Canada, Denmark, Finland, Ireland, Israel, Italy, Norway, Portugal, Russia, Serbia, Spain, Sweden, Ukraine and United Kingdom (NCT02443155)
  • 02 Sep 2014 Discontinued - Phase-I for Rheumatoid arthritis in Germany (IV, SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top